Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 217 articles: HTML format

Single Articles

May 2024
1. HOVHANNISYAN M, Zemankova P, Nehasil P, Matejkova K, et al
   Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.
   Cancer. 2024 May 8. doi: 10.1002/cncr.35337.
   PubMed     Abstract available
   
   
   
2. GUO H, Malone KE, Heckbert SR, Li CI, et al
   Statin use and risks of breast cancer recurrence and mortality.
   Cancer. 2024 May 6. doi: 10.1002/cncr.35362.
   PubMed     Abstract available
   
   
   April 2024
3. BERNSTEIN-MOLHO R, Shhada NA, Laitman Y, Netzer I, et al
   Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed >/=50 years.
   Cancer. 2024 Apr 17. doi: 10.1002/cncr.35329.
   PubMed     Abstract available
   
   
   
4. VANNIER AGL, Dhungana A, Zhao F, Chen N, et al
   Validation of the RSClin risk calculator in the National Cancer Data Base.
   Cancer. 2024;130:1210-1220.
   PubMed     Abstract available
   
   
   
5. NIERENGARTEN MB
   Routine estradiol testing recommended for women at high risk of breast cancer.
   Cancer. 2024;130:1014.
   PubMed    
   
   
   
6. NIERENGARTEN MB
   Cardiotoxicity of breast cancer drugs requires additional monitoring.
   Cancer. 2024;130:1013-1014.
   PubMed    
   
   
   
7. DELEIRE T, Mitchell JM, De La Cruz L, Isaacs C, et al
   Nonclinical factors associated with the treatment of older women with newly diagnosed low-grade ductal carcinoma in situ.
   Cancer. 2024;130:1041-1051.
   PubMed     Abstract available
   
   
   March 2024
8. WANG X, O'Regan RM
   Breast cancer therapy in China: Introducing the Special Collection.
   Cancer. 2024 Mar 25. doi: 10.1002/cncr.35288.
   PubMed    
   
   
   
9. NIERENGARTEN MB
   FDA approves capivasertib with fulvestrant for breast cancer.
   Cancer. 2024;130:835-836.
   PubMed    
   
   
   
10. WU J, Wang W, Gao L, Shao X, et al
    Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Cancer. 2024 Mar 14. doi: 10.1002/cncr.35270.
    PubMed     Abstract available
    
    
    
11. PUKLIN LS, Ferrucci LM, Harrigan M, McGowan C, et al
    Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35280.
    PubMed     Abstract available
    
    
    
12. ZHENG Q, Yan H, He Y, Wang J, et al
    An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35248.
    PubMed     Abstract available
    
    
    February 2024
13. HOU X, Li X, Han Y, Xu H, et al
    Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35261.
    PubMed     Abstract available
    
    
    
14. VERSLUIS MAJ, Raijmakers NJH, Baars A, van den Beuken-van Everdingen MHJ, et al
    Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study.
    Cancer. 2024;130:609-617.
    PubMed     Abstract available
    
    
    
15. LI X, Luo S, Fu W, Huang M, et al
    Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35228.
    PubMed     Abstract available
    
    
    
16. NGUYEN SM, Tran HTT, Long J, Shrubsole MJ, et al
    Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer.
    Cancer. 2024 Feb 6. doi: 10.1002/cncr.35229.
    PubMed     Abstract available
    
    
    January 2024
17. XIONG W, Xu T, Liu X, Zhang L, et al
    Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35206.
    PubMed     Abstract available
    
    
    
18. QU F, Lu R, Liu Q, Wu X, et al
    Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35205.
    PubMed     Abstract available
    
    
    
19. SMITH KL, Zhao F, Mayer IA, Tevaarwerk AJ, et al
    Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35187.
    PubMed     Abstract available
    
    
    
20. WANG J, Xia YC, Tian BX, Li JT, et al
    Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
    Cancer. 2024 Jan 13. doi: 10.1002/cncr.35176.
    PubMed     Abstract available
    
    
    
21. ZHOU X, Liu M, Zheng Z, Cao X, et al
    Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population-based study.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35166.
    PubMed     Abstract available
    
    
    
22. LIANG X, Zhang L, Gui X, Di L, et al
    Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35174.
    PubMed     Abstract available
    
    
    
23. AGGARWAL A, Han L, Lewis D, Costigan J, et al
    Association of travel time, patient characteristics, and hospital quality with patient mobility for breast cancer surgery: A national population-based study.
    Cancer. 2024 Jan 8. doi: 10.1002/cncr.35153.
    PubMed     Abstract available
    
    
    
24. SATHISHKUMAR K, Sankarapillai J, Mathew A, Nair RA, et al
    Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme.
    Cancer. 2024 Jan 6. doi: 10.1002/cncr.35188.
    PubMed     Abstract available
    
    
    
25. BHATT R, van den Hout A, Antoniou AC, Shah M, et al
    Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors.
    Cancer. 2024 Jan 4. doi: 10.1002/cncr.35183.
    PubMed     Abstract available
    
    
    
26. PRINSLOO S, Kaptchuk TJ, De Ridder D, Lyle R, et al
    Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial.
    Cancer. 2024;130:300-311.
    PubMed     Abstract available
    
    
    December 2023
27. AKKOC MUSTAFAYEV FN, Shukla MA, Lanier A, Milton DR, et al
    Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35159.
    PubMed     Abstract available
    
    
    
28. EOM KY, Koroukian SM, Dong W, Kim U, et al
    Accounting for Medicaid expansion and regional policy and programs to advance equity in cancer prevention in the United States.
    Cancer. 2023;129:3915-3927.
    PubMed     Abstract available
    
    
    
29. ZHANG S, Guo L, Zhang Z, Liu X, et al
    Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35142.
    PubMed     Abstract available
    
    
    November 2023
30. WILLIAMS AD, Ruth K, Shaikh SS, Vasigh M, et al
    Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35136.
    PubMed     Abstract available
    
    
    
31. OZTEKIN S, Hooning MJ, van Deurzen CHM, Dietvorst AHP, et al
    The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35125.
    PubMed     Abstract available
    
    
    
32. JI J, Bae M, Sun CL, Wildes TM, et al
    Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.
    Cancer. 2023 Nov 14. doi: 10.1002/cncr.35105.
    PubMed     Abstract available
    
    
    
33. GALI K, Orban E, Ozga AK, Mohl A, et al
    Does breast cancer modify the long-term relationship between lifestyle behaviors and mortality? A prospective analysis of breast cancer survivors and population-based controls.
    Cancer. 2023 Nov 11. doi: 10.1002/cncr.35104.
    PubMed     Abstract available
    
    
    
34. YU T, Lu Y, Fang J, Jiang X, et al
    Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Cancer. 2023 Nov 11. doi: 10.1002/cncr.35096.
    PubMed     Abstract available
    
    
    
35. LIN M, Luo T, Jin Y, Zhong X, et al
    HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis.
    Cancer. 2023 Nov 7. doi: 10.1002/cncr.35101.
    PubMed     Abstract available
    
    
    
36. LI J, Jiang Z
    Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects.
    Cancer. 2023 Nov 3. doi: 10.1002/cncr.35093.
    PubMed     Abstract available
    
    
    
37. ZHU J, Wang L, Gong W, Li X, et al
    Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study.
    Cancer. 2023 Nov 2. doi: 10.1002/cncr.35095.
    PubMed     Abstract available
    
    
    October 2023
38. SOROURI K, Sella T, Rosenberg SM, Loucks M, et al
    Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35066.
    PubMed     Abstract available
    
    
    
39. LI Y, Cao J, Wang J, Wu W, et al
    Association of the m(6) A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer.
    Cancer. 2023 Oct 20. doi: 10.1002/cncr.35048.
    PubMed     Abstract available
    
    
    
40. WHITE RL JR, Wallander ML, Leighliter ME, Sha W, et al
    Assessing trends in breast care surveillance metrics after implementing surgeon-specific tracking and performance reporting in a large, integrated cancer network.
    Cancer. 2023;129:3230-3238.
    PubMed     Abstract available
    
    
    
41. WILSON BE, Desnoyers A, Nadler MB, Amir E, et al
    Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021.
    Cancer. 2023;129:3318-3325.
    PubMed     Abstract available
    
    
    
42. KUDIARASU C, Lopez P, Galvao DA, Newton RU, et al
    What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high-risk of breast cancer? A systematic review and network meta-analysis.
    Cancer. 2023 Oct 3. doi: 10.1002/cncr.35043.
    PubMed     Abstract available
    
    
    
43. LEE J, Park S, Jung HA, Lee SH, et al
    A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
    Cancer. 2023;129:2966-2974.
    PubMed     Abstract available
    
    
    September 2023
44. SMEDSLAND SK, Falk RS, Reinertsen KV, Kiserud CE, et al
    Burden of late effects in a nationwide sample of long-term breast cancer survivors.
    Cancer. 2023 Sep 30. doi: 10.1002/cncr.35019.
    PubMed     Abstract available
    
    
    
45. MITCHELL JM, DeLeire T, Isaacs C
    Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer-related adverse health events.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35009.
    PubMed     Abstract available
    
    
    
46. SHEN S, Chen Y, Carpio A, Chang C, et al
    Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
    Cancer. 2023 Sep 25. doi: 10.1002/cncr.34928.
    PubMed     Abstract available
    
    
    
47. MALCOMSON FC, Wiggins C, Parra-Soto S, Ho FK, et al
    Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and cancer risk: A systematic review and meta-analysis.
    Cancer. 2023;129:2655-2670.
    PubMed     Abstract available
    
    
    
48. GANGULY AP, Baker KK, Redman MW, McClintock AH, et al
    Racial disparities in the screening mammography continuum within a heterogeneous health care system.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    
49. NYROP KA, Kelly EA, Teal R, Muss HB, et al
    Clinician perspectives on patient-centered conversations about weight management with patients with early breast cancer.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    
50. PADAMSEE TJ, Stover DG, Tarver WL, Washington CM, et al
    Turning the Page on Breast Cancer in Ohio: Lessons learned from implementing a multilevel intervention to reduce breast cancer mortality among Black women.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    
51. GLASER KM, Dauphin C, Johnson D, Harris N, et al
    Advancing community-academic partnerships to achieve breast health equity: Applying the community-based participatory model to build capacity for sustained impact.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    
52. KO NY, Fikre TG, Buck AK, Restrepo E, et al
    Breast cancer survivorship experiences among Black women.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    
53. BEA VJ, An A, Gordon AM, Antoine FS, et al
    Mammography screening beliefs and barriers through the lens of Black women during the COVID-19 pandemic.
    Cancer. 2023;129.
    PubMed     Abstract available
    
    
    August 2023
54. SARA G, Lambeth C, Burgess P, Curtis J, et al
    Breast screening participation and degree of spread of invasive breast cancer at diagnosis in mental health service users, a population linkage study.
    Cancer. 2023 Aug 26. doi: 10.1002/cncr.35002.
    PubMed     Abstract available
    
    
    
55. KWAN ML, Valice E, Ergas IJ, Roh JM, et al
    Alcohol consumption and prognosis and survival in breast cancer survivors: The Pathways Study.
    Cancer. 2023 Aug 9. doi: 10.1002/cncr.34972.
    PubMed     Abstract available
    
    
    
56. MALMGREN JA, Atwood MK, Kaplan HG
    Persistence of patient-detected breast cancer over time: 1990-2019.
    Cancer. 2023 Aug 8. doi: 10.1002/cncr.34973.
    PubMed     Abstract available
    
    
    July 2023
57. GEFFEN SR, Poteat T, Dean LT, Malone J, et al
    Engaging black sexual minority women in breast cancer research: Lessons in community partnerships.
    Cancer. 2023 Jul 25. doi: 10.1002/cncr.34960.
    PubMed     Abstract available
    
    
    
58. WIESE D, Stroup AM, Islami F, Mattes M, et al
    Geographic diffusion of digital mammography in the United States.
    Cancer. 2023;129:2144-2151.
    PubMed     Abstract available
    
    
    June 2023
59. ROY AM, Kumarasamy VM, Dhakal A, O'Regan R, et al
    A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm.
    Cancer. 2023 Jun 22. doi: 10.1002/cncr.34904.
    PubMed     Abstract available
    
    
    
60. SPRAGUE BL, Ichikawa L, Eavey J, Lowry KP, et al
    Breast cancer risk characteristics of women undergoing whole-breast ultrasound screening versus mammography alone.
    Cancer. 2023 Jun 12. doi: 10.1002/cncr.34768.
    PubMed     Abstract available
    
    
    
61. FARVID MS, Spence ND, Rosner BA, Barnett JB, et al
    Associations of low-carbohydrate diets with breast cancer survival.
    Cancer. 2023 Jun 10. doi: 10.1002/cncr.34819.
    PubMed     Abstract available
    
    
    
62. PLEASANT VA, Purkiss AS, Merjaver SD
    Redefining the "crown": Approaching chemotherapy-induced alopecia among Black patients with breast cancer.
    Cancer. 2023;129:1629-1633.
    PubMed    
    
    
    
63. RENTSCHER KE, Bethea TN, Zhai W, Small BJ, et al
    Epigenetic aging in older breast cancer survivors and non-cancer controls: preliminary findings from the Thinking and Living with Cancer (TLC) Study.
    Cancer. 2023 Jun 1. doi: 10.1002/cncr.34818.
    PubMed     Abstract available
    
    
    May 2023
64. THOMAS TH, Bender C, Donovan HS, Murray PJ, et al
    The feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game for women with advanced breast or gynecologic cancer.
    Cancer. 2023 May 27. doi: 10.1002/cncr.34887.
    PubMed     Abstract available
    
    
    
65. MANDELBLATT JS, Ruterbusch JJ, Thompson HS, Zhou X, et al
    Association between major discrimination and deficit accumulation in African American cancer survivors: The Detroit Research on Cancer Survivors Study.
    Cancer. 2023;129:1557-1568.
    PubMed     Abstract available
    
    
    
66. LU X, He M, Yu L, Gou Z, et al
    Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
    Cancer. 2023;129:1492-1501.
    PubMed     Abstract available
    
    
    
67. SPENCER JC, Noel L, Shokar NK, Pignone MP, et al
    Understanding the role of access in Hispanic cancer screening disparities.
    Cancer. 2023;129:1569-1578.
    PubMed     Abstract available
    
    
    April 2023
68. LEHRER S, Rheinstein PH
    Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10.
    Cancer. 2023 Apr 27. doi: 10.1002/cncr.34828.
    PubMed    
    
    
    
69. LASHEN AG, Toss MS, Rakha EA
    Reply to "Increased survival of women with luminal breast cancer and progesterone receptor immunohistochemical expression of greater than 10%".
    Cancer. 2023 Apr 27. doi: 10.1002/cncr.34826.
    PubMed    
    
    
    
70. MANDELBLATT JS, Small BJ, Zhou X, Nakamura ZM, et al
    Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34784.
    PubMed     Abstract available
    
    
    
71. CONROY SM, Von Behren J, Kwan ML, Kushi LH, et al
    Neighborhood attributes and cardiovascular disease risk in breast cancer survivors: The Pathways Study.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34794.
    PubMed     Abstract available
    
    
    
72. KOIZUMI T, Sugishita Y, Suzuki-Takahashi Y, Nara K, et al
    Oncofertility-related psycho-educational therapy for young adult patients with breast cancer and their partners: randomized controlled trial.
    Cancer. 2023 Apr 21. doi: 10.1002/cncr.34796.
    PubMed     Abstract available
    
    
    
73. LEI F, Vanderpool RC, McLouth LE, Romond EH, et al
    Influence of depression on breast cancer treatment and survival: A Kentucky population-based study.
    Cancer. 2023 Apr 17. doi: 10.1002/cncr.34676.
    PubMed     Abstract available
    
    
    
74. LIGIBEL JA, Zheng Y, Barry WT, Sella T, et al
    Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study.
    Cancer. 2023 Apr 5. doi: 10.1002/cncr.34779.
    PubMed     Abstract available
    
    
    
75. NELSON BE, Saleem S, Damodaran S, Somaiah N, et al
    Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
    Cancer. 2023 Apr 4. doi: 10.1002/cncr.34773.
    PubMed     Abstract available
    
    
    
76. SAAVEDRA C, Gion M, Cortes J, Llombart-Cussac A, et al
    Top advances of the year: Breast cancer.
    Cancer. 2023 Apr 4. doi: 10.1002/cncr.34752.
    PubMed     Abstract available
    
    
    
77. TRAPANI D, Mayer EL
    What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?
    Cancer. 2023;129:986-988.
    PubMed    
    
    
    March 2023
78. 
    Erratum to "Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation".
    Cancer. 2023 Mar 30. doi: 10.1002/cncr.34781.
    PubMed    
    
    
    
79. WEISS A, Martinez-Saez O, Waks AG, Laws A, et al
    Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34750.
    PubMed     Abstract available
    
    
    
80. NIERENGARTEN MB
    Advances in breast cancer presented in San Antonio.
    Cancer. 2023;129:817-818.
    PubMed    
    
    
    
81. MORRELL BL, Morrell MB, Ball JA, Ochoa AC, et al
    Disparities in the use of screening breast magnetic resonance imaging persist in Louisiana after the Affordable Care Act: A question of access, policy, institutional support, or something else?
    Cancer. 2023;129:829-833.
    PubMed     Abstract available
    
    
    
82. METCALFE KA, Gronwald J, Tung NM, McCuaig JM, et al
    The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    Cancer. 2023;129:901-907.
    PubMed     Abstract available
    
    
    
83. NEUMAN HB, Schumacher JR, Edge SB, Ruddy KJ, et al
    The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01).
    Cancer. 2023 Mar 6. doi: 10.1002/cncr.34656.
    PubMed     Abstract available
    
    
    February 2023
84. HYDE ET, LaCroix AZ, Evenson KR, Howard AG, et al
    Accelerometer-measured physical activity and postmenopausal breast cancer incidence in the Women's Health Accelerometry Collaboration.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34699.
    PubMed     Abstract available
    
    
    
85. LOWRY KP, Ichikawa L, Hubbard RA, Buist DSM, et al
    Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
    Cancer. 2023 Feb 15. doi: 10.1002/cncr.34679.
    PubMed     Abstract available
    
    
    
86. GOYAL RK, Chen H, Abughosh SM, Holmes HM, et al
    Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
    Cancer. 2023 Feb 9. doi: 10.1002/cncr.34675.
    PubMed     Abstract available
    
    
    
87. 
    Collagen type XII linked with poor overall survival in breast cancer.
    Cancer. 2023;129:331-332.
    PubMed    
    
    
    January 2023
88. REEDER-HAYES KE, Jackson BE, Baggett CD, Kuo TM, et al
    Race, geography, and risk of breast cancer treatment delays: A population-based study 2004-2015.
    Cancer. 2023 Jan 23. doi: 10.1002/cncr.34573.
    PubMed     Abstract available
    
    
    
89. JIN J, Cao J, Li B, Li T, et al
    Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
    Cancer. 2023 Jan 18. doi: 10.1002/cncr.34618.
    PubMed     Abstract available
    
    
    
90. LASHEN AG, Toss MS, Mongan NP, Green AR, et al
    The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
    Cancer. 2023 Jan 18. doi: 10.1002/cncr.34655.
    PubMed     Abstract available
    
    
    
91. RAMADAS K, Basu P, Mathew BS, Muwonge R, et al
    Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.
    Cancer. 2023;129:272-282.
    PubMed     Abstract available
    
    
    
92. LICAJ I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, et al
    Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.
    Cancer. 2023 Jan 15. doi: 10.1002/cncr.34643.
    PubMed     Abstract available
    
    
    
93. MELIS M, Schroyen G, Leenaerts N, Smeets A, et al
    The impact of mindfulness on cancer-related cognitive impairment in breast cancer survivors with cognitive complaints.
    Cancer. 2023 Jan 10. doi: 10.1002/cncr.34640.
    PubMed     Abstract available
    
    
    
94. PARISE CA, Caggiano V
    The association of race/ethnicity in male breast cancer survival within similar comorbidity cohorts.
    Cancer. 2023 Jan 3. doi: 10.1002/cncr.34592.
    PubMed     Abstract available
    
    
    
95. 
    Updated ASCO guidelines for patients with HER2-positive breast cancer.
    Cancer. 2023;129:10.
    PubMed    
    
    
    December 2022
96. ATKINS SLP, Zimmer AS
    Neurologic complications of breast cancer.
    Cancer. 2022 Dec 20. doi: 10.1002/cncr.34518.
    PubMed     Abstract available
    
    
    
97. NIERENGARTEN MB
    Molecular insights into triple-negative breast cancer metastasis: Epithelial- mesenchymal transition: There is a need to better understand the molecular drivers behind triple-negative breast cancer to help curb the incidence of metastasis: There is a
    Cancer. 2022;128:4174.
    PubMed    
    
    
    
98. HOPPER JL, Nguyen TL, Li S
    What if the age at which a woman started regular mammographic screening depended on her risk, not age?
    Cancer. 2022;128:4179-4181.
    PubMed    
    
    
    
99. LAVASANI SM, Somlo G, Yost SE, Frankel PH, et al
    Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
    Cancer. 2022 Dec 14. doi: 10.1002/cncr.34589.
    PubMed     Abstract available
    
    
    November 2022
100. GU J, Tong T, Xu D, Cheng F, et al
     Deep learning radiomics of ultrasonography for comprehensively predicting tumor and axillary lymph node status after neoadjuvant chemotherapy in breast cancer patients: A multicenter study.
     Cancer. 2022 Nov 19. doi: 10.1002/cncr.34540.
     PubMed     Abstract available
     
     
     
101. MALLARD J, Hucteau E, Schott R, Trensz P, et al
     Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer.
     Cancer. 2022 Nov 17. doi: 10.1002/cncr.34533.
     PubMed     Abstract available
     
     
     
102. 
     Liquid biopsy prototype assay for breast cancer.
     Cancer. 2022;128:3905.
     PubMed    
     
     
     
103. VALLANCE JK, Friedenreich CM, Wang Q, Matthews CE, et al
     Associations of device-measured physical activity and sedentary time with quality of life and fatigue in newly diagnosed breast cancer patients: Baseline results from the AMBER cohort study.
     Cancer. 2022 Nov 11. doi: 10.1002/cncr.34531.
     PubMed     Abstract available
     
     
     October 2022
104. ELLINGTON TD, Henley SJ, Wilson RJ, Miller JW, et al
     Trends in breast cancer mortality by race/ethnicity, age, and US census region, United States horizontal line 1999-2020.
     Cancer. 2022 Oct 30. doi: 10.1002/cncr.34503.
     PubMed     Abstract available
     
     
     
105. KRUL IM, Boekel NB, Kramer I, Janus CPM, et al
     Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
     Cancer. 2022 Oct 25. doi: 10.1002/cncr.34464.
     PubMed     Abstract available
     
     
     
106. DURHAM DD, Abraham LA, Roberts MC, Khan CP, et al
     Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis.
     Cancer. 2022 Oct 19. doi: 10.1002/cncr.34365.
     PubMed     Abstract available
     
     
     
107. GENNARO M, Maccauro M, Mariani L, Listorti C, et al
     Occurrence of breast-cancer-related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial.
     Cancer. 2022 Oct 19. doi: 10.1002/cncr.34498.
     PubMed     Abstract available
     
     
     
108. REN Y, Kebede MA, Ogunleye AA, Emerson MA, et al
     Burden of lymphedema in long-term breast cancer survivors by race and age.
     Cancer. 2022 Oct 12. doi: 10.1002/cncr.34489.
     PubMed     Abstract available
     
     
     
109. WARREN LEG, Niman SM, Remolano MC, Landry JM, et al
     Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
     Cancer. 2022 Oct 10. doi: 10.1002/cncr.34441.
     PubMed     Abstract available
     
     
     
110. DHAKAL A, Anders CK
     Screening brain MRI in inflammatory breast cancer: Is it time?
     Cancer. 2022 Oct 10. doi: 10.1002/cncr.34442.
     PubMed    
     
     
     
111. JACOBS JM, Post K, Massad K, Horick NK, et al
     A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
     Cancer. 2022;128:3541-3551.
     PubMed     Abstract available
     
     
     
112. COLONNA M, Grosclaude P, Bouvier AM, Goungounga J, et al
     Health status of prevalent cancer cases as measured by mortality dynamics (cancer vs. noncancer): Application to five major cancers sites.
     Cancer. 2022;128:3663-3673.
     PubMed     Abstract available
     
     
     September 2022
113. LI Y, Li WW, Yuan L, Xu B, et al
     Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?
     Cancer. 2022 Sep 20. doi: 10.1002/cncr.34468.
     PubMed     Abstract available
     
     
     
114. SNYDER RA, Hu CY, DiBrito SR, Chang GJ, et al
     Association of Medicaid expansion with racial disparities in cancer stage at presentation.
     Cancer. 2022;128:3340-3351.
     PubMed     Abstract available
     
     
     
115. WEISER R, Polychronopoulou E, Klimberg VS
     Reply to "The use of national datasets to evaluate outcomes for invasive lobular carcinoma".
     Cancer. 2022;128:3418-3419.
     PubMed    
     
     
     
116. MARMOR S, Hui JYC, White MJ, Tuttle TM, et al
     The use of national datasets to evaluate outcomes for invasive lobular carcinoma.
     Cancer. 2022;128:3416-3417.
     PubMed    
     
     
     
117. LEONE JP, Hassett MJ, Leone J, Tolaney SM, et al
     Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer.
     Cancer. 2022 Sep 7. doi: 10.1002/cncr.34448.
     PubMed     Abstract available
     
     
     August 2022
118. MAKHNOON S, Chen M, Levin B, Ensinger M, et al
     Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes.
     Cancer. 2022 Aug 23. doi: 10.1002/cncr.34429.
     PubMed     Abstract available
     
     
     
119. KNERR S, Guo B, Mittendorf KF, Feigelson HS, et al
     Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.
     Cancer. 2022;128:3090-3098.
     PubMed     Abstract available
     
     
     
120. QIU JQ, Zhang WL, Fang X, Cui T, et al
     Survival analysis in a prediction model for early systemic recurrence in breast cancer.
     Cancer. 2022 Aug 15. doi: 10.1002/cncr.34417.
     PubMed    
     
     
     
121. OSAKO T, Matsuura M, Tsuda H, Noguchi S, et al
     Reply to "Survival analysis in a prediction model for early systemic recurrence in breast cancer".
     Cancer. 2022 Aug 15. doi: 10.1002/cncr.34415.
     PubMed    
     
     
     
122. PATEL R, Hovstadius M, Kier MW, Moshier EL, et al
     Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
     Cancer. 2022 Aug 10. doi: 10.1002/cncr.34426.
     PubMed     Abstract available
     
     
     
123. LEHRER S, Rheinstein PH
     Breast cancer and body weight changes of young women in the UK Biobank cohort.
     Cancer. 2022 Aug 9. doi: 10.1002/cncr.34423.
     PubMed    
     
     
     
124. 
     Trastuzumab deruxtecan beats trastuzumab emtansine in lowered disease progression, death.
     Cancer. 2022;128:2852.
     PubMed    
     
     
     
125. 
     First person profile: Monica Morrow, MD: The chief of the Breast Service at Memorial Sloan Kettering Cancer Center (MSKCC) has made a lasting impact on breast surgical oncology: The chief of the Breast Service at Memorial Sloan Kettering Cancer Center
     Cancer. 2022;128:2850-2851.
     PubMed    
     
     
     
126. LEHRER S, Rheinstein PH
     Neither tamoxifen nor aromatase inhibitors increase the risk of Parkinson disease in the UK Biobank cohort.
     Cancer. 2022;128:2997-2998.
     PubMed    
     
     
     
127. SOLDATO D, Havas J, Crane TE, Presti D, et al
     Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancer.
     Cancer. 2022 Aug 1. doi: 10.1002/cncr.34401.
     PubMed     Abstract available
     
     
     
128. HOXHAJ A, Drissen MMCM, Vos JR, Bult P, et al
     The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome.
     Cancer. 2022;128:2883-2891.
     PubMed     Abstract available
     
     
     July 2022
129. BARGON CA, Young-Afat DA, Ikinci M, Braakenburg A, et al
     Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction-A systematic review and meta-analysis.
     Cancer. 2022 Jul 27. doi: 10.1002/cncr.34393.
     PubMed     Abstract available
     
     
     
130. MOUBADDER L, Collin LJ, Nash R, Switchenko JM, et al
     Drivers of racial, regional, and socioeconomic disparities in late-stage breast cancer mortality.
     Cancer. 2022 Jul 22. doi: 10.1002/cncr.34391.
     PubMed     Abstract available
     
     
     
131. KOELMEYER LA, Gaitatzis K, Dietrich MS, Shah CS, et al
     Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention.
     Cancer. 2022 Jul 7. doi: 10.1002/cncr.34377.
     PubMed     Abstract available
     
     
     
132. HYLAND CJ, Manrique OJ, Weiss A, Broyles JM, et al
     Preventive strategies for breast cancer-related lymphedema: Working toward optimal patient selection.
     Cancer. 2022 Jul 7. doi: 10.1002/cncr.34374.
     PubMed    
     
     
     
133. O'ROURKE K
     Breast cancer overdiagnosis through mammograms is lower than previous estimates.
     Cancer. 2022;128:2398-2399.
     PubMed    
     
     
     
134. CASANOVA NL, LeClair AM, Xiao V, Mullikin KR, et al
     Development of a workflow process mapping protocol to inform the implementation of regional patient navigation programs in breast oncology.
     Cancer. 2022;128 Suppl 13:2649-2658.
     PubMed     Abstract available
     
     
     
135. BATTAGLIA TA, Gunn CM, Bak SM, Flacks J, et al
     Patient navigation to address sociolegal barriers for patients with cancer: A comparative-effectiveness study.
     Cancer. 2022;128 Suppl 13:2623-2635.
     PubMed     Abstract available
     
     
     
136. CATHCART-RAKE EJ, Sanft T, Tevaarwerk AJ
     Weight gain after breast cancer diagnosis: It's complicated....
     Cancer. 2022 Jul 1. doi: 10.1002/cncr.34343.
     PubMed    
     
     
     
137. SELLA T, Zheng Y, Tan-Wasielewski Z, Rosenberg SM, et al
     Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors.
     Cancer. 2022 Jul 1. doi: 10.1002/cncr.34342.
     PubMed     Abstract available
     
     
     June 2022
138. RAUH-HAIN JA, Zubizarreta J, Nitecki R, Melamed A, et al
     Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study.
     Cancer. 2022 Jun 29. doi: 10.1002/cncr.34371.
     PubMed     Abstract available
     
     
     
139. WATSON NW, Wander SA, Shatzel JJ, Al-Samkari H, et al
     Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
     Cancer. 2022 Jun 29. doi: 10.1002/cncr.34367.
     PubMed     Abstract available
     
     
     
140. SITTENFELD SMC, Zabor EC, Hamilton SN, Kuerer HM, et al
     A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancer.
     Cancer. 2022 Jun 17. doi: 10.1002/cncr.34352.
     PubMed     Abstract available
     
     
     
141. HREBINKO KA, Bryce CL, Downs-Canner S, Diego EJ, et al
     Cost-effectiveness of Choosing Wisely guidelines for axillary observation in women older than age 70 years with hormone receptor-positive, clinically node-negative, operable breast tumors.
     Cancer. 2022;128:2258-2268.
     PubMed     Abstract available
     
     
     
142. KHOSROW-KHAVAR F, Azoulay L, Montastruc JL, Montastruc F, et al
     Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
     Cancer. 2022;128:2339-2347.
     PubMed     Abstract available
     
     
     
143. ALTUNDAG K
     Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer.
     Cancer. 2022 Jun 7. doi: 10.1002/cncr.34340.
     PubMed    
     
     
     
144. CAO L, Stabellini N, Amin AL, Montero AJ, et al
     Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer".
     Cancer. 2022 Jun 7. doi: 10.1002/cncr.34339.
     PubMed    
     
     
     
145. CARROLL JE, Olmstead R, Haque R, Irwin MR, et al
     Accelerated mononuclear cell telomere attrition in breast cancer survivors with depression history: A 2-year longitudinal cohort study.
     Cancer. 2022 Jun 7. doi: 10.1002/cncr.34329.
     PubMed     Abstract available
     
     
     
146. HARBECK N, Burstein HJ, Hurvitz SA, Johnston S, et al
     A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
     Cancer. 2022;128 Suppl 11:2209-2223.
     PubMed     Abstract available
     
     
     
147. O'ROURKE K
     Compression sleeves reduce lymphedema after lymph node dissection: In women who had breast cancer surgery to remove their axillary lymph nodes, the sleeves helped prevent arm swelling: In women who had breast cancer surgery to remove their axillary ly
     Cancer. 2022;128:2049-2050.
     PubMed    
     
     
     
148. JOUNG RH, Nelson H, Mullett TW, Kurtzman SH, et al
     A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
     Cancer. 2022;128:2119-2125.
     PubMed     Abstract available
     
     
     
149. O'BRIEN KM, Sandler DP
     Reply to "Vitamin D and breast cancer: Stop torturing the data!"
     Cancer. 2022 Jun 1. doi: 10.1002/cncr.34274.
     PubMed    
     
     
     
150. BRAILLON A
     Vitamin D and breast cancer: Stop torturing the data!
     Cancer. 2022 Jun 1. doi: 10.1002/cncr.34272.
     PubMed    
     
     
     May 2022
151. KIM G, Pastoriza JM, Qin J, Lin J, et al
     Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.
     Cancer. 2022 May 17. doi: 10.1002/cncr.34241.
     PubMed     Abstract available
     
     
     
152. JONES VC, Kruper L, Mortimer J, Ashing KT, et al
     Understanding drivers of the Black:White breast cancer mortality gap: A call for more robust definitions.
     Cancer. 2022 May 17. doi: 10.1002/cncr.34243.
     PubMed    
     
     
     
153. KORIC A, Chang CP, Mark B, Rowe K, et al
     Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study.
     Cancer. 2022 May 13. doi: 10.1002/cncr.34224.
     PubMed     Abstract available
     
     
     
154. ZHANG Y, Mao X, Yu X, Huang X, et al
     Bone mineral density and risk of breast cancer: A cohort study and Mendelian randomization analysis.
     Cancer. 2022 May 5. doi: 10.1002/cncr.34252.
     PubMed     Abstract available
     
     
     
155. WEISER R, Polychronopoulou E, Hatch SS, Haque W, et al
     Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
     Cancer. 2022;128:1738-1747.
     PubMed     Abstract available
     
     
     
156. LAU-MIN KS, Li Y, Eads JR, Mamtani R, et al
     Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma.
     Cancer. 2022;128:1853-1862.
     PubMed     Abstract available
     
     
     April 2022
157. O'BRIEN KM, Harmon QE, Jackson CL, Diaz-Santana MV, et al
     Vitamin D concentrations and breast cancer incidence among Black/African American and non-Black Hispanic/Latina women.
     Cancer. 2022 Apr 25. doi: 10.1002/cncr.34198.
     PubMed     Abstract available
     
     
     
158. LIGIBEL JA, Pierce LJ, Bender CM, Crane TE, et al
     Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey.
     Cancer. 2022 Apr 20. doi: 10.1002/cncr.34231.
     PubMed     Abstract available
     
     
     
159. O'ROURKE K
     Virginia G. Kaklamani, MD, highlights important news from SABCS: Updates from research on therapies for the treatment of breast cancer show promise: Updates from research on therapies for the treatment of breast cancer show promise.
     Cancer. 2022;128:1557-1558.
     PubMed    
     
     
     
160. ANDERSON BM, White JR
     Improving the well-being of women with ductal carcinoma in situ: A worthy goal with an unclear route to success.
     Cancer. 2022;128:1571-1573.
     PubMed    
     
     
     
161. ROSENBERG SM, Gierisch JM, Revette AC, Lowenstein CL, et al
     "Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ.
     Cancer. 2022;128:1676-1683.
     PubMed     Abstract available
     
     
     
162. MELKONIAN SC, Jim MA, Pete D, Poel A, et al
     Cancer disparities among non-Hispanic urban American Indian and Alaska Native populations in the United States, 1999-2017.
     Cancer. 2022;128:1626-1636.
     PubMed     Abstract available
     
     
     
163. HAYATI Z, Montazeri V, Shivappa N, Hebert JR, et al
     The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study.
     Cancer. 2022 Apr 7. doi: 10.1002/cncr.34183.
     PubMed     Abstract available
     
     
     
164. DUVAL A, Davis CG, Khoo EL, Romanow H, et al
     Mindfulness-based stress reduction and cognitive function among breast cancer survivors: A randomized controlled trial.
     Cancer. 2022 Apr 6. doi: 10.1002/cncr.34209.
     PubMed     Abstract available
     
     
     
165. CAO L, Towe CW, Shenk R, Stabellini N, et al
     A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysis.
     Cancer. 2022 Apr 1. doi: 10.1002/cncr.34200.
     PubMed     Abstract available
     
     
     
166. TSURUDA KM, Larsen M, Roman M, Hofvind S, et al
     Cumulative risk of a false-positive screening result: A retrospective cohort study using empirical data from 10 biennial screening rounds in BreastScreen Norway.
     Cancer. 2022;128:1373-1380.
     PubMed     Abstract available
     
     
     
167. BOROSUND E, Ehlers SL, Clark MM, Andrykowski MA, et al
     Digital stress management in cancer: Testing StressProffen in a 12-month randomized controlled trial.
     Cancer. 2022;128:1503-1512.
     PubMed     Abstract available
     
     
     March 2022
168. BYCHKOVSKY BL, Lo MT, Yussuf A, Horton C, et al
     Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics.
     Cancer. 2022;128:1275-1283.
     PubMed     Abstract available
     
     
     
169. BERLIN NL, Abrahamse P, Momoh AO, Katz SJ, et al
     Perceived financial decline related to breast reconstruction following mastectomy in a diverse population-based cohort.
     Cancer. 2022;128:1284-1293.
     PubMed     Abstract available
     
     
     
170. COHEN MG, Althouse AD, Arnold RM, Bulls HW, et al
     Hope and advance care planning in advanced cancer: Is there a relationship?
     Cancer. 2022;128:1339-1345.
     PubMed     Abstract available
     
     
     
171. OWUSU C, Margevicius S, Nock NL, Austin K, et al
     A randomized controlled trial of the effect of supervised exercise on functional outcomes in older African American and non-Hispanic White breast cancer survivors: Are there racial differences in the effects of exercise on functional outcomes?
     Cancer. 2022 Mar 15. doi: 10.1002/cncr.34184.
     PubMed     Abstract available
     
     
     
172. BALLINGER TJ, Jiang G, Shen F, Miller KD, et al
     Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
     Cancer. 2022 Mar 14. doi: 10.1002/cncr.34173.
     PubMed     Abstract available
     
     
     
173. RIDGEWAY JL, Jenkins SM, Borah BJ, Suman VJ, et al
     Evaluating educational interventions to increase breast density awareness among Latinas: A randomized trial in a Federally Qualified Health Center.
     Cancer. 2022;128:1038-1047.
     PubMed     Abstract available
     
     
     February 2022
174. OSAKO T, Matsuura M, Yotsumoto D, Takayama S, et al
     A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study.
     Cancer. 2022 Feb 28. doi: 10.1002/cncr.34144.
     PubMed     Abstract available
     
     
     
175. POTERALA JE, Wisinski KB
     Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy.
     Cancer. 2022 Feb 25. doi: 10.1002/cncr.34158.
     PubMed    
     
     
     
176. CAI YW, Shao ZM, Yu KD
     De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.
     Cancer. 2022 Feb 25. doi: 10.1002/cncr.34155.
     PubMed     Abstract available
     
     
     
177. 
     Erratum to "Trajectories of fear of cancer recurrence in young breast cancer survivors".
     Cancer. 2022 Feb 17. doi: 10.1002/cncr.34142.
     PubMed    
     
     
     
178. KUMAR S, Usmanova G, Nair TS, Srivastava VK, et al
     Implementation of a large-scale breast cancer early detection program in a resource-constrained setting: real-world experiences from 2 large states in India.
     Cancer. 2022 Feb 8. doi: 10.1002/cncr.34114.
     PubMed     Abstract available
     
     
     
179. 
     Erratum to "Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status".
     Cancer. 2022 Feb 2. doi: 10.1002/cncr.34077.
     PubMed    
     
     
     
180. MAMTANI A, Sevilimedu V, Le T, Morrow M, et al
     Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy?
     Cancer. 2022;128:471-478.
     PubMed     Abstract available
     
     
     January 2022
181. TRAMA A, Tittarelli A, Barigelletti G, Botta L, et al
     Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort.
     Cancer. 2022;128:364-372.
     PubMed     Abstract available
     
     
     
182. MALLA RR, Vasudevaraju P, Vempati RK, Rakshmitha M, et al
     Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
     Cancer. 2022 Jan 6. doi: 10.1002/cncr.34084.
     PubMed     Abstract available
     
     
     
183. ARUN BK, Peterson SK, Sweeney LE, Bluebond RD, et al
     Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
     Cancer. 2022;128:94-102.
     PubMed     Abstract available
     
     
     December 2021
184. WONG SM, Ajjamada L, Weiss AC, Prakash I, et al
     Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
     Cancer. 2021 Dec 17. doi: 10.1002/cncr.34065.
     PubMed     Abstract available
     
     
     
185. DE ROOIJ BH, Oerlemans S, van Deun K, Mols F, et al
     Symptom clusters in 1330 survivors of 7 cancer types from the PROFILES registry: A network analysis.
     Cancer. 2021;127:4665-4674.
     PubMed     Abstract available
     
     
     
186. CALIP GS, Wade NB, Guadamuz JS, Wang X, et al
     Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data.
     Cancer. 2021 Dec 7. doi: 10.1002/cncr.34045.
     PubMed    
     
     
     
187. CONNOR AE, Kaur M, Sheng JY, Hayes JH, et al
     Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: Impact of cardiovascular disease and clinical characteristics.
     Cancer. 2021 Dec 7. doi: 10.1002/cncr.33889.
     PubMed     Abstract available
     
     
     
188. TESCH ME, Speers C, Diocee RM, Gondara L, et al
     Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
     Cancer. 2021 Dec 2. doi: 10.1002/cncr.33982.
     PubMed     Abstract available
     
     
     
189. CADET T, Pinheiro A, Karamourtopoulos M, Jacobson AR, et al
     Effects by educational attainment of a mammography screening patient decision aid for women aged 75 years and older.
     Cancer. 2021;127:4455-4463.
     PubMed     Abstract available
     
     
     November 2021
190. PHILLIPS SM, Penedo FJ, Collins LM, Solk P, et al
     Optimization of a technology-supported physical activity promotion intervention for breast cancer survivors: Results from Fit2Thrive.
     Cancer. 2021 Nov 23. doi: 10.1002/cncr.34012.
     PubMed     Abstract available
     
     
     
191. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
     Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
     Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
     PubMed     Abstract available
     
     
     
192. YU AYL, Thomas SM, DiLalla GD, Greenup RA, et al
     Disease characteristics and mortality among Asian women with breast cancer.
     Cancer. 2021 Nov 18. doi: 10.1002/cncr.34015.
     PubMed     Abstract available
     
     
     
193. HAY A
     Pricing transparency among several needs for patients with high-risk breast cancer.
     Cancer. 2021;127:4122-4123.
     PubMed    
     
     
     
194. LEWIS DR, Siembida EJ, Seibel NL, Smith AW, et al
     Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016.
     Cancer. 2021;127:4277-4286.
     PubMed     Abstract available
     
     
     
195. KAUR M, Joshu CE, Visvanathan K, Connor AE, et al
     Trends in breast cancer incidence rates by race/ethnicity: Patterns by stage, socioeconomic position, and geography in the United States, 1999-2017.
     Cancer. 2021 Nov 3. doi: 10.1002/cncr.34008.
     PubMed     Abstract available
     
     
     
196. SEEWALDT VL, Bernstein L
     Reply to Corrections: Breast cancer screening guidelines for young women of color.
     Cancer. 2021 Nov 3. doi: 10.1002/cncr.33989.
     PubMed    
     
     
     
197. GORDON PB, Berg WA
     Corrections: Breast cancer screening guidelines for young women of color.
     Cancer. 2021 Nov 3. doi: 10.1002/cncr.33988.
     PubMed    
     
     
     
198. IP EH, Saldana S, Miller KD, Carlos RC, et al
     Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.
     Cancer. 2021 Nov 2. doi: 10.1002/cncr.33992.
     PubMed     Abstract available
     
     
     
199. DILLER ML, Master VA
     Integrative surgical oncology: A model of acute integrative oncology.
     Cancer. 2021;127:3929-3938.
     PubMed     Abstract available
     
     
     October 2021
200. NIERENGARTEN MB
     Higher mortality risk in African American women with triple-negative breast cancer.
     Cancer. 2021;127:3712-3713.
     PubMed    
     
     
     
201. WEISS MC, Hibbs JE, Buckley ME, Danese SR, et al
     A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment.
     Cancer. 2021 Oct 12. doi: 10.1002/cncr.33906.
     PubMed     Abstract available
     
     
     
202. MURUGAPPAN MN, King-Kallimanis BL, Mangir C, Howie L, et al
     Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer.
     Cancer. 2021 Oct 11. doi: 10.1002/cncr.33959.
     PubMed     Abstract available
     
     
     
203. JATOI I, Kunkler IH
     Omission of sentinel node biopsy for breast cancer: Historical context and future perspectives on a modern controversy.
     Cancer. 2021 Oct 6. doi: 10.1002/cncr.33960.
     PubMed     Abstract available
     
     
     
204. SCHAPIRA L, Zheng Y, Gelber SI, Poorvu P, et al
     Trajectories of fear of cancer recurrence in young breast cancer survivors.
     Cancer. 2021 Oct 6. doi: 10.1002/cncr.33921.
     PubMed     Abstract available
     
     
     
205. GARCIA SF, Gray RJ, Sparano JA, Tevaarwerk AJ, et al
     Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy.
     Cancer. 2021 Oct 6. doi: 10.1002/cncr.33939.
     PubMed     Abstract available
     
     
     
206. BRUNELLE CL, Ag AG
     The important role of nighttime compression in breast cancer-related lymphedema treatment.
     Cancer. 2021 Oct 6. doi: 10.1002/cncr.33942.
     PubMed    
     
     
     
207. MCNEELY ML, Dolgoy ND, Rafn BS, Ghosh S, et al
     Nighttime compression supports improved self-management of breast cancer-related lymphedema: A multicenter randomized controlled trial.
     Cancer. 2021 Oct 6. doi: 10.1002/cncr.33943.
     PubMed     Abstract available
     
     
     
208. FALKSON CI
     Adjuvant tamoxifen adherence in male patients with breast cancer: An ongoing challenge.
     Cancer. 2021 Oct 1. doi: 10.1002/cncr.33898.
     PubMed    
     
     
     
209. OKE O, Niu J, Chavez-MacGregor M, Zhao H, et al
     Adjuvant tamoxifen adherence in men with early-stage breast cancer.
     Cancer. 2021 Oct 1. doi: 10.1002/cncr.33899.
     PubMed     Abstract available
     
     
     
210. BERNSTEIN-MOLHO R, Galmor L, Laitman Y, Segev S, et al
     Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
     Cancer. 2021;127:3599-3604.
     PubMed     Abstract available
     
     
     September 2021
211. NIERENGARTEN MB
     Trio of mammography studies demonstrate enhanced screening effectiveness: Recent research on the use of adjunctive technologies and expanded-age screening provides promising results for women with dense breasts.
     Cancer. 2021;127:3279-3280.
     PubMed    
     
     
     
212. KOTSOPOULOS J, Kim SJ, Armel S, Bordeleau L, et al
     An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
     Cancer. 2021;127:3183-3193.
     PubMed     Abstract available
     
     
     June 2021
213. PRINTZ C
     Less-educated minority women have less 3-D mammography access.
     Cancer. 2021;127:1953.
     PubMed    
     
     
     
214. HENSING WL, Poplack SP, Herman CR, Sutcliffe S, et al
     Racial differences in no-show rates for screening mammography.
     Cancer. 2021;127:1857-1863.
     PubMed     Abstract available
     
     
     May 2021
215. PRINTZ C
     Immune Factors Tied to Aggressive Breast Cancers in Black Patients.
     Cancer. 2021;127:1546.
     PubMed    
     
     
     April 2021
216. TAIT SD, Ren Y, Horton CC, Oshima SM, et al
     Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women.
     Cancer. 2021 Apr 7. doi: 10.1002/cncr.33473.
     PubMed     Abstract available
     
     
     February 2021
217. LEE RT, Kwon N, Wu J, To C, et al
     Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
     Cancer. 2021 Feb 1. doi: 10.1002/cncr.33324.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.